Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus by Meyer, Olivier C et al.
Open Access
Available online http://arthritis-research.com/content/11/3/R87
Page 1 of 8
(page number not for citation purposes)
Vol 11 No 3 Research article
Anti-C1q antibodies antedate patent active glomerulonephritis in 
patients with systemic lupus erythematosus
Olivier C Meyer1, Pascale Nicaise-Roland2, Nolwenn Cadoudal2, Sabine Grootenboer-Mignot2, 
Elisabeth Palazzo1, Gilles Hayem1, Philippe Dieudé1 and Sylvie Chollet-Martin2
1Rheumatology Unit, Bichat Hospital, APHP, 46 rue Henri Huchard, 75018 Paris, France
2Immunology Unit, Bichat Hospital, APHP, 46 rue Henri Huchard, 75018 Paris, France
Corresponding author: Olivier C Meyer, olivier.meyer@bch.aphp.fr
Received: 28 Jan 2009 Revisions requested: 20 Feb 2009 Revisions received: 5 Jun 2009 Accepted: 10 Jun 2009 Published: 10 Jun 2009
Arthritis Research & Therapy 2009, 11:R87 (doi:10.1186/ar2725)
This article is online at: http://arthritis-research.com/content/11/3/R87
© 2009 Meyer et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Autoantibodies against C1q correlate with lupus
nephritis. We compared titers of anti-C1q and anti-dsDNA in 70
systemic lupus erythematosus patients with (n = 15) or without
(n = 55) subsequent biopsy-proven lupus nephritis.
Methods The 15 patients with subsequent lupus nephritis had
anti-C1q assays during clinical flares (mean Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI), 10.0 ± 4.7;
range, 3 to 22) before the diagnosis of lupus nephritis (median,
24 months; range 3 to 192). Among the 55 others, 33 patients
had active lupus (mean SLEDAI, 10.3 ± 6.2; range, 4 to 30)
without renal disease during follow-up (median 13 years; range
2 to 17 years) and 22 had inactive lupus (mean SLEDAI, 0;
range, 0 to 3).
Results Anti-C1q titers were elevated in 15/15 (100%) patients
who subsequently developed nephritis (class IV, n = 14; class
V, n = 1) and in 15/33 (45%) patients without renal disease (P
< 0.001). The median anti-C1q titer differed significantly
between the groups (P  = 0.003). Anti-C1q titers were
persistently positive at the time of glomerulonephritis diagnosis
in 70% (7/10) of patients, with no difference in titers compared
with pre-nephritis values (median, 147 U/ml; interquartile range
(IQR), 69 to 213 versus 116 U/ml; 50 to 284, respectively).
Titers decreased after 6 months' treatment with
immunosuppressive drugs and corticosteroids (median, 76 U/
ml; IQR, 33 to 106) but remained above normal in 6/8 (75%)
patients. Anti-dsDNA antibodies were increased in 14/15
(93.3%) patients with subsequent nephritis and 24/33 (72.7%)
patients without nephritis (P = ns). Anti-C1q did not correlate
with anti-dsDNA or the SLEDAI in either group.
Conclusions Anti-C1q elevation had 50% positive predictive
value (15/30) and 100% (18/18) negative predictive value for
subsequent class IV or V lupus nephritis.
Introduction
Active proliferative glomerulonephritis is a serious manifesta-
tion of systemic lupus erythematosus (SLE) that may exist at
disease onset or may develop later on during a flare. Clinical
nephritis develops in about 50% of patients with SLE. Early
diagnosis and rapid treatment of lupus nephritis are crucial to
improving survival in SLE patients [1]. The prognostic signifi-
cance of lupus nephritis indicates a need for identifying early
biomarkers that predict nephritis development [2-4].
A major pathogenic hypothesis is that SLE involves defective
renal clearance of immune complexes. Among immunological
parameters, consumption of the early components of the clas-
sical complement pathway, such as C1q and C4, is strongly
associated with the development of active SLE [5]. Low C1q
levels, although occasionally caused by a rare genetic abnor-
mality, are usually related to consumption by immune com-
plexes such as dsDNA–anti-dsDNA or nucleosomes–
antinucleosomes [6,7]. Another cause of low C1q levels is the
presence of anti-C1q antibodies with the formation of C1q/
anti-C1q immune complexes [8]. Anti-C1q antibodies have
dsDNA: double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; IQR: interquartile range; NPV: negative predictive value; PPV: positive 
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been described in patients with SLE [9-11] or other autoim-
mune diseases [12,13]. Their correlations with hypocomple-
mentemia and glomerulonephritis suggest that anti-C1q may
play a pathogenic role [14,15].
The aims of the present study were to determine the preva-
lence of anti-C1q antibodies in SLE patients with or without
lupus nephritis after a long follow-up period and to test the pre-
dictive value of the anti-C1q assay for subsequent lupus
nephritis. We also compared anti-C1q versus anti-dsDNA
antibodies (another candidate for predicting lupus nephritis)
regarding their ability to identify patients at high risk for lupus
nephritis [2,16-19].
Materials and methods
Patients
In this single-center retrospective study, 70 adults meeting at
least four of the 11 American College of Rheumatology criteria
for the classification of SLE [20] were recruited. These 70
patients were chosen among 115 SLE patients followed lon-
gitudinally by one of the authors (OCM). Patients were
selected based on the availability of stored serum samples.
In the 15 patients with lupus nephritis, we had stored (-20°C)
serum samples obtained at least 3 months before the onset of
clinical manifestations of nephritis, at a time when the disease
was active (Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) ≥ 4). Clinical nephritis was suspected if urinal-
ysis showed proteinuria >0.5 g/dl on a 24-hour urine collec-
tion and/or hematuria or cellular casts with or without
increased serum creatinine. Renal biopsies were performed
for all 15 patients with clinical nephritis. The findings were
classified according to the World Health Organization and
International Society of Nephrology/Renal Pathology Society
[21]. The renal disease was class IV in 14 patients and class
V in one patient.
In the remaining 55 patients the disease was either active
(SLEDAI ≥ 4) (n = 33) or inactive (n = 22) at the time of serum
sampling, and there was no evidence of lupus nephritis (no
low-grade proteinuria, hematuria, or cellular casts by routine
periodic urinalysis) at any time during follow-up (mean, 11.3 ±
5 years; range, 2 to 17 years). The SLE activity at periodic
serum sampling was defined based on the SLEDAI values in
the medical records [22]. In patients with subsequent lupus
nephritis, none of the renal parameters of the SLEDAI was
present at the time of first serum sampling. These patients had
active lupus without renal manifestations. At the time of the
renal flare, the renal SLEDAI ranged from 4 to 16 points (one
Table 1
Characteristics of patients with systemic lupus erythematosus
Active lupus with nephritis (n = 15) Active lupus without nephritis (n = 33) Inactive lupus without nephritis (n = 22)
Female/male 15/0 (100%) 28/5 (84.8%) 21/1 (95.5%)
Ethnicity
Caucasian 13 (86.7%) 20 (60.6%) 19 (86.4%)
Black 2 9 3
Asian 0 4 0
Age at serum sampling (years)
Median 30 28 35
Range 19 to 58 17 to 48 20 to 76
Duration of SLE (years) at serum sampling
Median 6 2.1 10
Range 0.25 to 36 0.1 to 14.1 1.1 to 49
Duration of follow-up (years) (from SLE diagnosis to last visit)
Median 13.5 13 19
Range 5.9 to 23 2 to 17 4 to 52
SLEDAI at first serum sampling (points)
Median 10a 80
Range 4–22 4–30 0 to 3
SLE, systemic lupus erythematosus. aSystemic Lupus Erythematosus Disease Activity Index (SLEDAI) was calculated before the onset of renal 
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to three parameters). The main characteristics of the two
patient groups are presented in Table 1.
Patients with class IV or class III glomerulonephritis were
treated with either intermittent intravenous cyclophosphamide
infusions (0.6 g/m2/infusion) (13 patients) or oral mycopheno-
late mofetil (two patients) and with high-dose prednisolone (1
mg/kg/day) with or without initial intravenous methylpred-
nisolone pulses (1 g). The single patient with class V glomer-
ulonephritis also had central nervous system involvement, and
was given intermittent intravenous cyclophosphamide infu-
sions (12 infusions in all) after an incomplete response to aza-
thioprine and high-dose oral corticosteroids.
In 11 of the 15 patients with nephritis, we obtained the anti-
C1q and anti-dsDNA titers at the time of renal biopsy (n = 10)
and/or after 6 months' immunosuppressive treatment (and: n
= 7/ or: n = 1). Of the eight patients whose anti-C1q status
was determined after immunosuppressive treatment, three
patients were in complete remission and five patients were in
partial remission of the nephritis. Partial remission was defined
as any of the following: decrease in urinary protein excretion by
>50% and to <3 g/day with a serum albumin level of ≥ 30 g/l,
and either stable renal function or a serum creatinine decrease
to <130 μmol/l for patients whose baseline serum creatinine
was 130 to 260 μmol/l. (None of the patients had a baseline
creatinine level >260 μmol/l.)
The hospital ethics committee approved the present study and
all participants gave their written informed consent. The study
was conducted in accordance with the recommendations of
the Helsinki declaration and all investigations were those rou-
tinely required to evaluate the patients, each of whom gave
informed consent to all procedures.
Autoantibody assays
All autoantibody assays were performed on the stored serum
samples during the same run, by technicians who were
blinded to the patient groups.
IgG anti-C1q antibodies were determined using an ELISA with
purified human C1q (Bühlmann Laboratories, Schönenbuch,
Switzerland), according to the manufacturer's recommenda-
tions. Briefly, undigested purified human C1q served as the
antigen, and sera were diluted and incubated in high-salt
buffer (1 M NaCl). Optical densities were measured at 450 nm
and converted into units (U/ml) by plotting against the autoan-
tibody titer of the standards given by the manufacturer. The
cutoff value for defining a positive test was determined by the
manufacturer as 20 U/ml. With this cutoff value, 20% of 40
blood donors tested in our laboratory had positive tests. We
calculated an optimized cutoff value at the 98th percentile
(that is, 32 U/ml), which decreased the proportion of normal
blood donors with positive tests to 6%, as reported in the lit-
erature [23].
IgG anti-dsDNA antibodies were determined using an ELISA
with enzyme-linked immunoassay technology (PHADIA
GmBH, Freiburg, Germany), according to the manufacturer's
instructions. The cutoff value for a positive test result (15 U/
ml), as determined by the manufacturer by testing samples
from 400 healthy blood donors, corresponds to the 98th per-
centile. The fluorescent signal was converted to international
units (IU/ml) by plotting the value against the autoantibody titer
of World Health Organization standardized calibrators
(Wo80) supplied by the manufacturer.
Statistical analysis
Demographic, clinical, and histological characteristics are
reported as the mean (standard deviation) or n (%), as appro-
priate. Results of the ELISAs are given as the median (inter-
quartile range (IQR)). Nonparametric tests (Mann-Whitney U
test, and Spearman's rank correlation test) and Fisher's exact
test were used to compare the groups with and without lupus
nephritis. Sigma Stat software, version 3.5 (Systat Software
Inc., Chicago, IL, USA) was used for statistical analyses. P <
0.05 was considered significant.
Results
Study patients
The clinical characteristics of the study patients are presented
in Table 1. No significant differences were found between the
groups for the sex ratio, ethnicity, median age at serum sam-
pling, median follow-up duration from SLE diagnosis to the last
visit, or median SLEDAI at serum sampling in the two groups
with active SLE. The only significant difference between the
groups was a longer median duration of SLE in the nephritis
group (6 years; range, 0.25 to 36 years) compared with the
group without nephritis (2.1 years; range, 0.1 to 14.1 years) (P
< 0.003). The median time from serum sampling to the diag-
nosis of lupus nephritis (15 patients) was 1.2 years (range, 0.3
to 16 years). The time from serum sampling to lupus nephritis
was <12 months in 5 patients and ≥ 12 months in 10 patients
(1 to 2 years in four patients, 2 to 5 years in five patients, and
16 years in one patient). Lupus treatment at the time of serum
sampling in the 15 patients with subsequent nephritis involved
low-dose prednisolone (<0.5 mg/kg/day) and hydroxychloro-
quine in eight patients, high-dose prednisolone (≥ 0.5 mg/kg/
day) and intermittent intravenous cyclophosphamide in two
patients, low-dose prednisolone and oral azathioprine (2 mg/
kg/day) or methotrexate (0.4 mg/kg/week) in two patients
each, and hydroxychloroquine with no corticosteroid in one
patient.
Anti-C1q antibodies
Anti-C1q antibodies were found in all 15 (100%) patients with
subsequent lupus nephritis, compared with 15 (45%) of 33
patients with active SLE but no nephritis (P < 0.001) and five
(23%) of 22 patients with inactive SLE and no nephritis. The
median plasma anti-C1q titer in the 33 patients with active
non-nephritis lupus was 28 U/ml (IQR, 13 to 113 U/ml), com-Arthritis Research & Therapy    Vol 11 No 3    Meyer et al.
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pared with 116 U/ml (IQR, 612 to 172 U/ml) in the 15 patients
with lupus nephritis (P = 0.003) and 10 U/ml (IQR, 7 to 32 U/
ml) in the inactive non-nephritis group (Figure 1a). The sensi-
tivity of anti-C1q antibody was 15/15 (100%) for subsequent
severe lupus nephritis (class IV or class V). The specificity of
the anti-C1q assay was 95.7%. The positive predictive value
(PPV) for subsequent severe lupus nephritis was 15/30 (50%)
and the negative predictive value (NPV) was 18/18 (100%).
The time between serum sampling and subsequent clinical
lupus nephritis varied widely, from 3 months to 16 years. We
therefore divided the nephritis patients into two subgroups,
one with sampling-to-nephritis times <12 months (n = 5) and
the other with longer times (n = 10). Anti-C1q antibody titers
were not significantly different between these two groups
(median, 82 U/ml vs. 117 U/ml).
Serial anti-C1q assays were obtained in 11 of the 15 nephritis
patients. At renal biopsy, anti-C1q antibodies were present
with no significant titer variation in seven out of 10 patients;
the antibodies were absent in two patients, one of whom was
already treated with high-dose cyclophosphamide for trans-
verse myelitis. After 6 months' immunosuppressive treatment,
the anti-C1q titer decreased in eight out of eight patients
(median, 76.5 U/ml; IQR, 33 to 106) (Figure 2a) but remained
above normal in six out of eight patients.
Anti-dsDNA antibodies
Anti-dsDNA antibodies were detected in 14 (93.3%) of 15
patients with subsequent lupus nephritis, compared with 24
(72.7%) of 33 patients with active SLE and no nephritis (P =
ns) and nine (73%) patients with inactive SLE and no nephritis
(P  = ns). The median plasma anti-dsDNA titer in the 15
patients with nephritis was 115 IU/ml (IQR, 74 to 296 IU/ml),
compared with 24 IU/ml (IQR, 10 to 70 IU/ml) in the 33
patients with active SLE and no nephritis (P = 0.01) and 13
IU/ml (IQR, 5 to 23 IU/ml) in the 22 patients with inactive SLE
(P = 0.008) (Figure 1b). The NPV of anti-dsDNA antibodies for
subsequent lupus nephritis was 9/10 (90%). The only patient
who subsequently developed nephritis but had negative anti-
dsDNA antibodies (2 IU/ml) had class V membranous glomer-
ulonephritis 31 months after serum sampling.
At renal biopsy, the anti-dsDNA antibody test was positive (30
IU/ml). The sensitivity of anti-dsDNA for subsequent active
proliferative lupus nephritis was 14/14 (100%), the PPV was
14/38 (37%), and the NPV was 9/10 (90%). Combining anti-
C1q and anti-dsDNA led only to a slight improvement in the
PPV (58.3% instead of 50%); both antibodies were positive in
10 out of 33 (30.3%) patients with active nonrenal lupus and
in four out of 22 (18.2%) patients with inactive lupus. The NPV
decreased to 95.8% when both antibodies were used in com-
bination.
At the time of renal biopsy, nine out of 10 patients were posi-
tive for anti-dsDNA antibodies; the remaining patient, who pre-
viously had a weakly positive titer (19 IU/ml), had a negative
titer at the time of biopsy (14 IU/ml) (Figure 2b). Finally, six out
of eight patients had persistently low anti-dsDNA titers after 6
months of high-dose immunosuppressive drugs.
Correlations
Anti-C1q titers did not correlate with anti-dsDNA titers in
either group (data not shown). More specifically, anti-C1q tit-
ers in sera drawn before the onset of lupus nephritis did not
correlate with anti-dsDNA titers (P = 0.6). In the two groups of
Figure 1
Anti-C1q and anti-dsDNA titers in systemic lupus erythematosus  patients Anti-C1q and anti-dsDNA titers in systemic lupus erythematosus 
patients. Comparison of (a) anti-C1q and (b) anti-dsDNA titers in the 
three groups of systemic lupus erythematosus (SLE) patients. IQR, 
interquartile range.Available online http://arthritis-research.com/content/11/3/R87
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patients with active SLE (with and without lupus nephritis,
respectively), neither anti-C1q titers nor anti-dsDNA titers cor-
related with the SLEDAI value at serum sampling (Figure 3a,b).
In the nephritis group, the anti-dsDNA titer correlated strongly
with the SLEDAI value at sampling before the first renal mani-
festations (r  = 0.63, P  < 0.02). No correlation was found
between anti-dsDNA titers and  S L E D A I  v a l u e s  i n  t h e  4 8
patients with active SLE (15 patients with and 33 patients
without nephritis) (Figure 3b).
Discussion
The aim of the present study was to determine whether anti-
C1q antibodies predicted the subsequent development of
lupus nephritis. Among previous studies, all but one [23]
involved testing for anti-C1q at the time of the renal biopsy
showing active proliferative or nonproliferative lupus nephritis
[9,23-29]. In this setting, anti-dsDNA and other immunological
parameters such as low complement hemolytic 50, C3, and
C4 or the presence of antinucleosome showed moderate sen-
sitivity and a moderate NPV for lupus nephritis [10,19,30-32].
We looked at anti-C1q titers at a time when the patients had
no evidence of nephritis. Patients in whom nephritis developed
subsequently were more likely to have anti-C1q antibodies
(100%) than the other patients (45%), although the SLEDAI
(excluding renal parameters) at the time of sampling was sim-
ilar in the two groups before the first renal manifestation. The
median anti-C1q titer was higher in the group with subsequent
nephritis.
These data are consistent with the results of anti-C1q assays
using a similar method in serum samples taken at the time of
renal biopsy in 38 patients with proliferative (n = 26) or class
V (n = 2) lupus nephritis [23]. Anti-C1q was found in 97% of
patients with active proliferative nephritis, compared with 35%
of lupus patients with inactive nephritis and 25% of lupus
patients without nephritis [23]. Similar data were reported by
Horak and colleagues in a series of 33 patients [33] and by
Fang and colleagues in a series of 150 patients [29], all with
lupus nephritis.
Our data indicate that the PPV of anti-C1q is only fair, as nearly
one-half of the patients who still had no evidence of nephritis
at follow-up completion had positive tests for anti-C1q, some-
times with very high titers. The mean follow-up was 11.3 years
(median, 13 years) in this group, and we cannot rule out that
nephritis will develop later on in some of the patients, particu-
larly as the lower end of the follow-up range was only 2 years
(three patients, including one patient with a very high anti-C1q
titer).
With the caveat that we studied only a small number of
patients, and that we studied only a single time measurement
for a predictive value calculation of subsequent nephritis, the
high NPV of anti-C1q is of interest. A high NPV is extremely
helpful for identifying patients at low risk. All 14 patients with
Figure 2
Follow-up of anti-C1q and anti-dsDNA titers in systemic lupus ery- thematosus patients with nephritis Follow-up of anti-C1q and anti-dsDNA titers in systemic lupus ery-
thematosus patients with nephritis. Longitudinal follow-up of (a) anti-
C1q and (b) anti-dsDNA titers in systemic lupus erythematosus 
patients with nephritis. IQR, interquartile range.Arthritis Research & Therapy    Vol 11 No 3    Meyer et al.
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a subsequent diagnosis of class IV proliferative glomerulone-
phritis tested positive for anti-C1q at least 3 months before,
and sometimes as long as 16 years before, the first clinical
manifestation of renal disease. Anti-C1q antibody data at the
time of renal biopsy showed good concordance with data
obtained before the clinical manifestations of glomerulonephri-
tis in seven out of 10 patients. One patient with an anti-C1q
titer slightly above the cutoff value was diagnosed with class
V glomerulonephritis 31 months later and had a high anti-C1q
titer at the time of the renal biopsy. Another patient, whose
anti-C1q titer was slightly above the cutoff value, was diag-
nosed 13 months later with class IV glomerulonephritis and
had a negative anti-C1q test but was already treated with high-
dose cyclophosphamide for extra-renal SLE manifestations.
The anti-C1q test may remain positive, however, even after 6
months of immunosuppressive therapy (five out of eight (62%)
nephritis patients in our series, 30% in the study by Moroni
and colleagues [32], and 47% in the study by Fang and col-
leagues [29]). In our study, this finding may be related to the
fact that five out of eight patients achieved only partial
responses. Other possibilities include inadequacy of the
upper limit of normal determined in our laboratory in normal
control individuals. We chose the 98th percentile as the upper
limit of the normal, in keeping with many earlier studies. The
high NPV of anti-C1q in our study is consistent with previous
reports of anti-C1q values at the time of full-blown lupus
nephritis [10,23,27-29,32-36] or before the diagnosis of
lupus nephritis [23]. Moroni and colleagues reported a pro-
spective 6-year study in 228 patients with lupus nephritis [32].
Among flares of proliferative lupus nephritis, 20% occurred at
a time when anti-C1q titers were below the cutoff value, and
30% of patients were in remission of their nephritis at a time
when anti-C1q titers were elevated. The best model for pre-
dicting renal flares was a combination of anti-C1q with C3 and
C4 [32].
Anti-C1q titers did not correlate with the SLEDAI in patients
with subsequent lupus nephritis. These antibodies should not
be taken as a general marker of disease activity, in contrast to
anti-dsDNA antibodies [37]. Our finding is in contrast with a
recent report by Fang and colleagues that anti-C1q titers cor-
related well with the SLEDAI in 150 patients with renal SLE
[29]. This discrepancy may be ascribable to differences in the
patient populations and anti-C1q assays. In the study by Fang
and colleagues, the IgG subclass distribution of anti-C1q anti-
bodies suggested that IgG2 anti-C1q might be pathogenic
and that IgG3 anti-C1q might be the most specific biomarker
for monitoring disease activity (among patients in remission,
100% became negative for IgG3 anti-C1q compared with
53% negative for IgG2 anti-C1q).
Conclusions
Our data suggest that anti-C1q may be a good serological
marker for the subsequent development of active proliferative
glomerulonephritis in patients with SLE. Patients without anti-
C1q are at very low risk for severe proliferative glomerulone-
phritis (100% NPV in our study). Patients with anti-C1q anti-
bodies have an approximately 50% risk for lupus nephritis
within the next decade, and therefore require close renal mon-
itoring.
Figure 3
Correlation between the Systemic Lupus Erythematosus Disease Activ- ity Index and anti-C1q and anti-dsDNA titers Correlation between the Systemic Lupus Erythematosus Disease Activ-
ity Index and anti-C1q and anti-dsDNA titers. Patients included those 
with active systemic lupus erythematosus (SLE) with (n = 15) and with-
out (n = 33) subsequent lupus nephritis. The Systemic Lupus Ery-
thematosus Disease Activity Index (SLEDAI) (before lupus nephritis) 
did not correlate (a) with anti-C1q antibodies in the overall population 
of 48 active SLE patients or in the 15 lupus nephritis patients, or (b) 
with anti-dsDNA titers in the overall population of 48 patients. In the 15 
lupus nephritis patients, the SLEDAI showed a fair correlation with anti-
dsDNA titers (r = 0.63, P < 0.02).Available online http://arthritis-research.com/content/11/3/R87
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